It mimics the incretin hormones that regulate insulin and glucagon production

Ozempic (semaglutide) is a GLP-1 receptor agonist administered subcutaneously for type 2 diabetes management Lumps commonly form due to injection technique errors including inadequate site rotation, injecting too rapidly, or removing the needle too soon after injection Normal lumps are firm, mobile, mildly tender, and gradually reduce in size without warmth, spreading redness, or systemic symptoms Seek medical attention for progressive enlargement, increasing pain, signs of infection (warmth, discharge, fever), or difficulty breathing Prevention requires proper technique including systematic site rotation (23 cm from previous sites), keeping the needle in place for at least 6 seconds post-injection, and never reusing needles Lipohypertrophy (persistent rubbery lumps from repeated injections in the same area) impairs medication absorption and requires strict site avoidance Table of Contents Why Lumps Form After Ozempic Injections Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist administered subcutaneously for the management of type 2 diabetes mellitus

Absolute rates for the combined endpoint of fatal or nonfatal stroke: 1.8% (n=30 of 1648) with Ozempic injection and 2.8% (n=46 of 1649) with placebo
It provides a science-based method for aging vibrantly, supporting everything from muscle mitochondria to collagen in the cheeks
The improvements in metabolic health, particularly insulin sensitivity, are not just a byproduct of losing weight
How Can We Help